Clinical Report: FDA approves new treatment for FOP

Overview

The FDA has approved zilurgisertib (Atebrioz) for reducing new heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP). This approval follows a randomized trial demonstrating significant efficacy compared to placebo.

Background

Fibrodysplasia ossificans progressiva is a rare genetic disorder characterized by abnormal bone growth in muscles and connective tissues, leading to severe disability and early mortality.

Data Highlights

Key Findings

• Zilurgisertib is approved for adults and pediatric patients aged 12 years and older with FOP.
• The treatment led to a mean decrease of 3.2 cm³ in heterotopic ossification volume at week 24.
• In contrast, the placebo group experienced an increase of 24.6 cm³ in the same period.
• Common adverse effects include headache, joint pain, and upper respiratory tract infections.
• The FDA granted zilurgisertib fast track, priority review, and orphan drug designations.

Clinical Implications

Clinicians should be aware of the potential for fetal harm and the need for effective contraception in patients of reproductive potential.

Conclusion

The approval of zilurgisertib marks a significant milestone in the treatment of FOP, offering hope for improved management of this challenging condition.

Related Resources & Content

1. US Food and Drug Administration, FDA, 2026 -- FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva
2. mdspire news — FDA approves garetosmab for adults with FOP
3. MDSpire News — FDA Grants Accelerated Approval for OTOF Gene Therapy
4. the asco post — FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma
5. the asco post — New Approvals in Hematologic Malignancies, Skin Cancer, and Small Cell Lung Cancer
6. FDA Approves garetosmab for adults with FOP
7. FDA Grants Accelerated Approval for OTOF Gene Therapy
8. FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma
9. Introduction — ICCFOP
10. FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva | FDA
11. FDA Approves Second Treatment for Fibrodysplasia Ossificans Progressiva | FDA